1. Home
  2. Pharma
  3. Harbour Annouces Global…

Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)

Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)

Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)

Shots:
  • Under the licensing deal Harbour has global rights of A167 (excl. Greater China), to treat multiple solid and hematological cancers
  • Kelun-Biotech will receive an upfront of >$350mn in addition to royalties
  • A167 is under clinical Ph I & II in China targeting lymphoma and solid tumors
Click here to read full press release/ article | Ref: Harbour Biomed | Image:  Business wire

Post Views: 9
Tags:

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis
Pharma

Incyte Collaborates with Cellenkos for CK0804 to...

December 31, 2020
Roche Reports Results of Faricimab in Two Global P-III Studies for Diabetic Macular Edema
Clinical Trials

Roche Reports Results of Faricimab in Two...

December 22, 2020
CEPI to Invest ~$328M in Clover’s COVID-19 Vaccine Candidate
Regulatory

CEPI to Invest ~$328M in Clover’s COVID-19...

November 4, 2020
J&J Initiates Global P-III Clinical Study of its COVID-19 Vaccine
Biotech COVID-19

J&J Initiates Global P-III Clinical Study of...

September 24, 2020

Copyright ©2021 PharmaShots | Powered by Octavus Consulting